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he specificity and power of the cellular arm of the im-
 
mune system may provide new therapeutic approaches
to cancer. With the assumption that T cells might be able
to recognize and eliminate cancer cells with the same effi-
ciency as virus-infected cells, investigators have searched
many years for ways to trigger or amplify the patient’s inad-
equate immune response to tumors. Much attention has
 




 CTLs because most tumors





 CTLs are able to lyse tumor cells directly
upon recognition of peptide–MHC class I complexes ex-
pressed by the tumor, and their ability to eradicate large tu-
mor masses in vivo has been demonstrated. The focus in




 T cell responses is also ex-









 Th cells have re-
ceived far less attention, which is remarkable given the piv-
otal role of these cells in regulating most antigen-specific
immune responses. Until now, only a few Th epitopes de-





cells have been identified (1, 2). Three studies published in
this issue describe the identification of melanoma antigens




 T cells in the context of
MHC class II molecules (3–5). Charting the Th response
against human melanoma as well as other tumors is impor-
tant for the development of optimal anticancer vaccines
and for the design of other T cell–related therapeutic mo-
dalities in cancer.
 
Lessons Learned from Mouse Tumor Models.
 
Studies using
adoptively transferred purified T cell subsets or in vivo de-





 CTLs in antitumor immunity (for a









 T cells to the overall immune














 T cells, provided that IL-2 is given si-





 Th cells in the development of an ef-
fective antitumor tumor response was consistently found in




 T cells are
likely to play a diversified role in antitumor immunity that





 T cells in priming of CTLs is well docu-
mented (14), explaining why activated CTLs, but not naive





 T cells. Analysis of the participation of individual
T cell populations in the elimination of the Friend murine










 CTLs. Adoptive transfer studies









 subset were individually capable of
eradication of disseminated leukemia in tumor-bearing
mice (for a review, see reference 15). Thus, although the




 T cells are
not able to recognize this MHC class II–negative tumor di-
rectly, they are able to control tumor growth via a mecha-
nism that does not require CTLs (16). More recently, it





but also vaccination with an MuLV-derived Th epitope
(but not a control Th peptide) induced protection against a
subsequent challenge with MHC class II–negative, virus-
induced tumor cells (17). In this case, the protection in-








 T cells, as
depletion of either subset at the time of tumor challenge
abrogated the ability to control tumor outgrowth. Simulta-
neous vaccination with a tumor-specific CTL epitope and
the tumor-specific Th epitope, rather than an unrelated Th
epitope, resulted in strong synergistic protection. Taken to-
gether, these findings illustrate the relevance of identifying
and using tumor-specific Th epitopes even in the case of
MHC class II–negative tumors, and emphasize the impor-








cells to establish optimal immunity to cancer.
 







As evident from the experience in the MuLV tu-




 T cells can mediate sev-
eral functions influencing the outcome of tumor-specific





 T cells play in delivery of help for priming of tu-
mor-specific CTLs, resulting in important mechanistic in-
sights into this event. Accumulating evidence indicates that
for induction of MHC class I–restricted tumor-specific im-
munity, cross-presentation of antigens that have been cap-





Dissection of the cellular interactions involved in CTL
priming revealed that Th cells must recognize antigen on
the same APC that cross-presents the CTL epitope (22).
These findings explain the requirement for epitope linkage
between Th cell epitopes and CTL epitopes important for
induction of CTL responses (23), and could clarify the
view that help for CTLs is delivered through the release of
soluble factors such as IL-2 produced by Th cells in the
proximity of CTLs. Recently, however, it was shown that
T cell help for CTLs is critically dependent on interaction
between CD40L expressed by Th cells and CD40 ex-
pressed by APCs (24, 25). Indeed, a central role for CD40–
CD40L interactions in the generation of protective T cell–
mediated tumor immunity has been demonstrated (26, 27).
These interactions most likely empower the APCs to prime
CTLs, since help for CTL priming can be bypassed by acti-
vation of dendritic cells (DCs) through CD40 (28). Several
lines of evidence indicate that CD40 signaling is part of an
important pathway in T cell–dependent APC activation.
Recombinant soluble CD40L stimulates human monocytes
to release proinflammatory cytokines (29), whereas ligation




T cells triggers the production of IL-12. In the latter case,
IL-12 production by DCs was inhibited by blockade of




 T cell (30). Moreover, CD40 liga-
tion is a potent stimulus to upregulate the expression of
intercellular adhesion molecule 1 (ICAM-1), CD80, and
CD86 molecules (31, 32). Because CD40-induced activa-
tion of professional APCs results in the expression of co-
stimulatory molecules important for CTL priming, this ac-
tivation is likely to play an important role in the delivery of
T help to CTLs. In this model, the APC that cross-presents
antigen to both antigen-specific Th cells and CTLs acts as
an intermediary for the delivery of help to CTLs.
Appreciation of the fundamental role of the APC activa-
tion state to tune the outcome of T cell responsiveness
helps to explain why CTL responses against tumors, in-
cluding those induced by noninflammatory persistent tu-
mor viruses such as MuLV (and likely human papillomavi-
rus and Epstein-Barr virus), are dependent on T cell help,
whereas CTL responsiveness against acute disease-causing





 Th activity (33). The difference between
these two situations appears to reside in the fact that influ-
enza virus can directly infect and activate DCs to a pheno-





pendent fashion (28). However, under noninflammatory
conditions, such as in many allograft situations and in most
cancers, CTL responses are much more Th cell dependent





cells before they trigger T killer responses.





 Th cells participate in additional ef-
fector functions. Evidence that these other Th cell–depen-
dent effector mechanisms play an important role in the host
defence against tumors came from studies in the MuLV sys-




T cells are implicated in the activation of tumoricidal mac-
 
rophages involved in tumor clearance (15). More recently,
it was demonstrated in a model involving vaccination with
irradiated tumor cells, transduced to secrete GM-CSF, that




 T cells belonging to the Th1
or Th2 lineage can recruit and activate macrophages and
eosinophils, respectively (13). Protection against tumor
challenge was strongly associated with the presence of eosin-
ophils at the tumor challenge site as well as the production
of oxygen radicals by tumoricidal macrophages, since ge-
netically modified mice disabled to produce these radicals
were severely hampered in their ability to resist tumor
challenge. A significant fraction of CD8 knockout, but not
CD4 knockout animals, were able to successfully resist tu-





 T cell–mediated effector mechanisms.
As in the MuLV system, the tumor described above did
not express MHC class II molecules, emphasizing the no-





ated immunity can be successfully applied to counteract tu-
mors that lack or lose expression of MHC molecules.
 
Induction of Tumor-specific T Cell Tolerance.
 
The studies
described above, together with the identification of new




 T cells, bring fresh
encouragement to the development of anticancer immune
intervention schemes. However, manipulation of the im-
mune response to tumors in tumor-bearing hosts might be
actively frustrated by the tumor itself, as it has been re-





nonresponsiveness (34). The mechanism of tolerization is,
as yet, not clear, but it might mimic many aspects described
for tolerance induction to peripheral tissue antigens. Pe-








 T cells to antigens expressed outside the lym-
phoid system has been described in several models (35–37).
In these cases, tolerance is mediated by cross-presentation
of the antigen on bone marrow–derived APCs (36, 37). As
development and growth of tumors is initially not accom-
panied by inflammatory stimuli or stress to the immune
system, antigen derived from the tumor might be shunted
in the same cross-tolerizing pathway as reported for periph-
eral tissue antigens. In this way tumors, as close mimics of
the normal tissue from which they are derived, might
shrewdly use the T cell tolerizing state of certain bone mar-
row–derived APCs that normally guarantee tissue toler-
ance. This tolerization of both helpers and killers might
hamper immune intervention schemes that are based on
the induction or propagation of the T cell immune system
in tumor-bearing hosts. Knowledge about the epitopes rec-









will be instrumental to study whether such a scenario could
explain why certain tumors—for instance, melanoma—are
able to grow, despite the expression of potentially highly
immunogenic tumor antigens.




 Th cells can orches-
trate several effector functions that can cooperate in an ef-
fective antitumor response. Knowledge of the antigens and




 T cells is of crucial





role these cells play in the immune response to human tu-
mors, as well as for optimal use of the Th arm of the
immune system in the development of new anticancer
vaccine modalities. The studies published in this issue de-
scribing new MHC class II–restricted melanoma antigens









 T cells have in
immune attack directed against human tumors, and will be
of great benefit in optimizing tumor immunotherapy if the
rules of the murine models apply to the situation in cancer
patients.
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